PDGFRB and acute myeloid leukemia: Other studies, however, have shown worse outcomes in AML with PDGFRA and PDGFRB translocations treated with imatinib, particularly in patients with additional cytogenetic (e.g., complex karyotype) or molecular abnormalities, who had a median overall survival of 12.5 months (range, 2–20) [35,50,51,52].